Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm here for the science, and I think my early investment helped the company and has helped patients. Are you helping in some way?
Relief/aviptadil will be releasing the results of their covid trial 29 MAR (Mon). Will be interesting to see their 60 day data and if good is enough to get EUA
"black ops"--what happened with the weekly summary you were posting of the "shorters gain/loss" in CYDY stock?? You quit writing that book or the weekly chapters don't need updating or ??
You just said remdesivir's EUA should never have happened and that it was the government's fault. You also said you have tons of respect for the FDA and the CDC.
CytoDyn is trying to sell a treatment the world is desperate for and yet still has millions of vials just sitting there unwanted.
I will say in my last breath , please no Remdesivir
Unfortunately , probably not as important as Dr Fauci and Gilead in this situation ..
What is the saying in USA , it is not what you do , but who you know..
..something like that.....
But first time HGEN chaned primary endpoint it was was before interim results, because it has nothing to do with it.
And DSMC advising to add patients if tey see that study will not meet primary endpoint as it is now..
And this is your 3 primary endpoint in the trial . So many times changed.
..." Some of those secondary infections could hurt patients without Lenzilumab "
You right , and knowing that one don't add other potentially dangerous for these patients drugs..
https://www.reddit.com/r/CYDY/comments/me1phj/another_letter_to_janet_woodcock/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
This is a different study than the Imperial College London study. Coincidentally, both were published in Science Immunology.
Clonal expansion and activation of tissue-resident memory-like TH17 cells expressing GM-CSF in the lungs of patients with severe COVID-19
https://immunology.sciencemag.org/content/6/56/eabf6692?utm_campaign=SciMag&utm_source=JHubd&utm_medium=Twitter
Cytodyn was given guidance from the FDA
Why you think they excluding patients with ALL secondary infections ??
Mayo Clinic had 12 patients total ,
No one can say anything about safety of a drug after evaluating 12 patients..
The term "data mining" is a tool shorts use to distract from positive results. You'll see it being used when trying to draw attention away from positive data.
It is written everyplace what may happen when we suppress GM-CSF , this is not a secret ..
What might be a reason that all patients with secondary viral , bacterial , fungi infection are excluded from the study ..
If I completed a study I'd certainly extract the good points in a NY minute. Why wouldn't you? The bears call it mining and I call it using the facts to your advantage.
there is no way in hell would I short CYDY over a weekend.
I actually cant think of any other study changing 3 times primary endpoint in one study.
Possibility of immunosuppression is a reason for it.
Thank you. I think I may have somewhat worn out my welcome by some here, and I don't exactly get warm fuzzies when I post relatively infrequently on the CYDY board, either. But I know what I think, and why, and expressing those thoughts is more important to me than what others may think of me. Nothing I say is intended to offend anybody and I try to be respectful. I accept that others have different views.
Sometimes complete inhibition of GM-CSF may produce immunosuppression , this is why patients with any secondary infections , like viral , bacterial or fungi are not accepted to Lenzilumab study
And when we look at the protocol , they really accepting patients closer to moderate and not very severe or critical.
And according to the CEO , Lenzilumab reducing length of hospitalization of about 1 day compare to other treatment.
It's going to be interesting how the GM-CSF information that came out in UK study affects things. Lenz is given at an early stage of severe in the trial. So basically when a moderate patient is progressing to severe. When the trials started, it obviously wasn't practical to give an expensive mab to every mild patient. But the UK study found that the patients who eventually become severe and die have elevated GM-CSF even when they are mild without many symptoms. So it might not be impractical to give lenz early since it will only be a small fraction of mild patients who have elevated GM-CSF. Right now, the equipment doesn't exist to test every mild patient's blood. But those scanners are going to be built. Humanigen might even be in talks with the scientists from the UK trial about doing a collaboration where they test and HGEN treats. Lenz could end up being given to mild, moderate, and severe patients with the treatment coming earlier and earlier as more scanners are built. More government funding for trials should be forthcoming.
Another thing, $75,000 is exactly half of $150,000. So he and his wife might have gone halfsies (Nader probably had to borrow his half from her).
To my knowledge, there hasn't really been any other promising therapeutics to treat moderate to severe covid cases and then this merck pill pops out of no where.
Ahhhhh, Pourhassan says he put in $75,000 of his own money into the company
LOL! We both know how that goes...the filings however mentions no such record of it.
Thanks Don Don, what is the name of the business NP and "William" were engaged in?
Here it says he put $75,000 of his own money into CYDY. But I'm positive I once read that there was $150,000 that came from his wife's family.
https://www.bizjournals.com/portland/news/2020/09/17/embattled-cytodyn-ceo-is-undaunted-by-losses-setb.html?ana=TRUEANTHEMFB_PO&csrc=6398&utm_campaign=trueAnthem%3A%20Trending%20Content&utm_medium=trueAnthem&utm_source=facebook&fbclid=IwAR2XTG_54VvlqZrVEW7-eJqn0C5Y_Mm8VEBrxqYCSP3kYYNGDn3SIcbes3Q
CytoDyn’s first product, an HIV antibody therapy, showed some promise but the company was struggling. Pourhassan says he put in $75,000 of his own money into the company, while deferring his salary. He came on board as chief operating officer in 2008, before becoming president and CEO four years later.
This article talks a bit about it. The $150,000 injection must have come from a different interview.
https://www.bioprocessonline.com/doc/the-perilous-development-of-a-potential-biologic-blockbuster-0001
CytoDyn, the maker of leronlimab, was resurrected from the ashes in 2008 by an immigrant teacher with a PhD in mechanical engineering named Nader Pourhassan.
At the time, Pourhassan had been teaching mechanical engineering at the Center For Advanced Learning, a charter school in Gresham, OR while nurturing a few ancillary business partnerships. One of his partners, a 72-year-old named William, was holding 750,000 shares of a company called CytoDyn, which was then trading at a nickel. William, half desperate to unload his stake in the failing company, urged Pourhassan to meet CytoDyn’s CEO and help him turn things around. Pourhassan bristled. “I didn’t even know what biotechnology meant,” he tells me. “I wasn’t about to get involved.”
Pourhassan’s wife changed that paradigm, as spouses often do. She was weary of his frequent trips to China to nurture his business interests. She was convinced the CytoDyn project brought with it an opportunity to do something altruistic, to change peoples’ lives. “If it fails,” she reasoned, “we can always teach.” Her support sealed the deal. William helped Pourhassan sell off their business interests, and he went all-in on CytoDyn. Pourhassan joined the brink-of-bankruptcy organization as COO and was charged with its turnaround. For a year, he took no salary. His wife funded his travel, most of which was to raise enough funds to keep the company in the game.
So where was it said his m-i-l gave him $150K?
it was Nader who bought the company---???
Where might the documentation to support the above quote be located?
Right now the train is south bound
When Data comes out on HGEN you will either be in the stock or you will trying to get back in. There will be no catching the train if the data is positive.
CytoDyn should be hiring scientists. Infectious disease specialists. Basically, guys like Bruce Patterson. Or pharmaceutical specialists. Your family doctor is patently unqualified.
Don 4X, so, you're saying that a doctor who goes through all of the same medical training as, let's say a primary care doctor, but then decides to take that training further and specialize in a particular area by advancing their knowledge and skills suddenly become useless in all the other areas? Wow, who knew?
Maybe the CYDY retail army should descend upon Washington DC. Have speeches at the Lincoln Memorial and then march to Congress and break the doors down. Scratch "leronlimab saves lives" into the wood. Leave notes threatening members of Congress. They'll have no choice but to give leronlimab an EUA.
I heard something similar, however the 5 hours of energy only kicks day 3 and again on day 14. It’s a problem.
It's also true.
dr recknor is very accomplished very fine bio too.imo
osteopath is a licensed physician and can write scripts